High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients

Oncotarget

Volumn 7, Issue 22, 2016, Pages 33035-33045

  Wang, Hua ^a,b   Wang, Liang ^a,b   Liu, Wen Jian ^a,b   Xia, Zhong jun ^a,b   Huang, Hui Qiang ^a   Jiang, Wen Qi ^a   Li, Zhi Ming ^a   Lu, Yue ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Department of Colorectal Surgery   (China)

Author keywords

Asparaginase; Extranodal NK T cell lymphoma; Minimal residual disease; Prognosis; Soluble programmed cell death ligand 1

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; OXALIPLATIN; PREDNISONE; PROGRAMMED DEATH 1 LIGAND 1; VINCRISTINE; CD274 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CONFORMAL RADIOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; INTENSITY MODULATED RADIATION THERAPY; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NK T CELL LYMPHOMA; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; BLOOD; MORTALITY; PROGNOSIS; RECURRENT DISEASE; SURVIVAL RATE;

ADULT; B7-H1 ANTIGEN; BIOMARKERS, TUMOR; FEMALE; HUMANS; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; PROGNOSIS; RECURRENCE; SURVIVAL RATE;

EID: 84973568806     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8847     Document Type: Article

References (26)

1. Sabattini E, Bacci F, Sagramoso C and Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010; 102:83-87.
2. Lim MS, de Leval L and Quintanilla-Martinez L. Commentary on the 2008 WHO classification of mature Tand NK-cell neoplasms. Journal of hematopathology. 2009; 2:65-73.
3. Sun J, Yang Q, Lu Z, He M, Gao L, Zhu M, Sun L, Wei L, Li M, Liu C, Zheng J, Liu W, Li G and Chen J. Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification. American journal of clinical pathology. 2012; 138:429-434.
4. Cheung MM, Chan JK, Lau WH, Ngan RK and Foo WW. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. International journal of radiation oncology, biology, physics. 2002; 54:182-190.
5. Wang L, Wang WD, Xia ZJ, Zhang YJ, Xiang J and Lu Y. Combination of gemcitabine, L-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE/IIE extranodal natural killer/T cell lymphoma: a retrospective study in a cohort of 227 patients with long-term follow-up. Medical oncology (Northwood, London, England). 2014; 31:860.
6. Wang H, Wuxiao ZJ, Zhu J, Wang Z, Wang KF, Li S, Chen X, Lu Y and Xia ZJ. Comparison of gemcitabine, oxaliplatin and L-asparaginase and etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone as first-line chemotherapy in patients with stage IE to IIE extranodal natural killer/T-cell lymphoma: a multicenter retrospective study. Leukemia & lymphoma. 2015; 56:971-977.
7. Wang L, Wang ZH, Chen XQ, Li YJ, Wang KF, Xia YF and Xia ZJ. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer. 2013; 119:348-355.
8. Chambers CA, Kuhns MS, Egen JG and Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annual review of immunology. 2001; 19:565-594.
9. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE and Rosenberg SA. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009; 114:1537-1544.
10. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E and Chen L. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature medicine. 2002; 8:793-800.
11. Zou W and Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nature reviews Immunology. 2008; 8:467-477.
12. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England journal of medicine. 2012; 366:2443-2454.
13. Han L, Liu F, Li R, Li Z, Chen X, Zhou Z, Zhang X, Hu T, Zhang Y, Young K, Sun S, Wen J and Zhang M. Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma. Oncology letters. 2014; 8:1461-1469.
14. Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, Yu H, Fletcher CD, Freeman GJ, Shipp MA and Rodig SJ. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virusassociated malignancies. Clinical cancer research. 2013; 19:3462-3473.
15. Rossille D, Gressier M, Damotte D, Maucort-Boulch D, Pangault C, Semana G, Le Gouill S, Haioun C, Tarte K, Lamy T, Milpied N and Fest T. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. Leukemia. 2014; 28:2367-2375.
16. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515:568-571.
17. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H and Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumorinfiltrating lymphocytes and their PD-1 expression. Clinical cancer research. 2004; 10:5094-5100.
18. Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, Levionnois E, Nizard M, Si-Mohamed A, Besnier N, Gey A, Rotem-Yehudar R, Pere H, Tran T, Guerin CL, Chauvat A, et al. PD-1-expressing tumorinfiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer research. 2013; 73:128-138.
19. Qin T, Zeng YD, Qin G, Xu F, Lu JB, Fang WF, Xue C, Zhan JH, Zhang XK, Zheng QF, Peng RJ, Yuan ZY, Zhang L and Wang SS. High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer. Oncotarget. 2015; 6:33972-33981. doi: 10.18632/ oncotarget.5583.
20. Green MR, Rodig S, Juszczynski P, Ouyang J, Sinha P, O'Donnell E, Neuberg D and Shipp MA. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clinical cancer research. 2012; 18:1611-1618.
21. Wang B, Li XQ, Ma X, Hong X, Lu H and Guo Y. Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type. American journal of hematology. 2008; 83:795-799.
22. Wang H, Zhu JY, Liu CC, Zhu MY, Wang JH, Geng QR and Lu Y. Increased serum levels of interleukin-15 correlate with negative prognostic factors in extranodal NK/T cell lymphoma. Medical oncology (Northwood, London, England). 2015; 32:370.
23. Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, Lee DH, Huh J, Oh SY, Kwon HC, Kim HJ, Lee SI, Kim JH, Park J, Oh SJ, Kim K, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. Journal of clinical oncology. 2006; 24:612-618.
24. Zhang G, Hou J, Shi J, Yu G, Lu B and Zhang X. Soluble CD276 (B7-H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum. Immunology. 2008; 123:538-546.
25. Lin N, Song Y, Zheng W, Tu M, Xie Y, Wang X, Ping L, Ying Z, Zhang C, Deng L, Liu W and Zhu J. A prospective phase II study of L-asparaginase-CHOP plus radiation in newly diagnosed extranodal NK/Tcell lymphoma, nasal type. Journal of hematology & oncology. 2013; 6:44.
26. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of clinical oncology. 1999; 17:1244.